cryptoxanthin

Jay M. Symptoms not very bad. Karl L. My congestion cryptoxanthin allergies did seem to get better after cryptoxanthin several days...Marsha R. I had some better days. Erin C. I believe cryptoxanthin it helped to a certain extent. William R. Improved after 3 days. Nancy C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human cryptoxanthin body uses with the element cobalt. The unique properties of cobalt permit a chemical reaction that produces the rungs of the DNA ladder. These rungs are called nucleotides. For any human cell to divide, it must copy its own DNA. For this replication to occur, new rungs of the ladder must be provided with the cryptoxanthin help of B12.

In 1990 study in San Diego, CA the 5 active subjects with allergic rhinitis had a lowered total serum IgE from Day 0 to Day 90 while 4 placebo subjects, (2 with allergic rhinitis, 1 with asthma and 1 with both), had flat or increased IgE levels.4 In a randomized, double-blind, placebo controlled study of symptoms and serum IgE levels in San Diego, CA in mid-1991, subjects had allergic rhinitis and/or asthma. Serum was drawn at Day 0 and Day 30. Seven of the 10 active treated subjects had a reduction in total serum IgE levels. In 10 placebo treated subjects, 5 had levels of total serum IgE that stayed the same (plus or minus 5%), 3 decreased and 2 increased.5 Statistical analysis of the open-label study as well as the double-blind randomized placebo controlled study have shown a significant effect of vitamin B12 in lowering serum IgE concentrations.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 cryptoxanthin on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6